FOLFIRI regimen in advanced colorectal cancer: The experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  Maiello, Evaristo ^a,b   Gebbia, V ^c   Giuliani, F ^a   Paoletti, G ^d   Gebbia, N ^e   Borsellino, N ^f   Carteni G ^g   Pezzella, G ^h   Manzione, L ⁱ   Romito, S ^j   Lopez, M ^d   Colucci, G ^a,k  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c LA MADDALENA CANCER CENTER   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g Buccheri La Ferla Hospital   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ Ospedale Nord   (Italy)

^j SAN CARLO HOSPITAL   (Italy)

^k Cardarelli Hospital   (Italy)

more..

Author keywords

Colorectal cancer; Combination therapy; Fluorouracil; Folinic acid; Irinotecan

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; COLONY STIMULATING FACTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OXALIPLATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABDOMINAL CRAMP; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAIR LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; ONCOLOGY; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 30644457456     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi909     Document Type: Article

References (15)

1. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
2. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-308.
3. de Gramont A, Bosset JF, Rougier P et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 1997; 15: 808-815.
4. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 2000; 355: 1041-1047.
5. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
6. Maiello E, Gebbia V, Giuliani F et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomized phase II study of the Southern Italy Oncology group. Ann Oncol 2000; 11: 1045-1051.
7. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI vs FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).J Clin Oncol (in press)
8. Colucci G, Maiello E, Gebbia V et al. 5-Fluorouracil and levofolinic acid with or without recombinant interferon-2b in advanced colorectal cancer patients. A randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group. Cancer 1999; 85: 535-545.
9. Miller AB, Hoogstraten B, Staquet M, Winkler M: Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
10. de Gramont A, Bosset JF, Rougier P et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 1997; 15: 808-815.
11. Rougier P, Van Cutsem E, Bajetta E et al. Randomized trial of irinotecan versus fluorouracil by coninuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
12. Cunningham D, Pyrhonen S, James RD et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
13. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
14. Saltz LB, Meropol NJ, Loehrer PJ et al. Phase II of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
15. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.